GLP-1 weight loss treatment in Kuala Lumpur

GLP-1 medication is considered for adults whose weight is affecting their health, and only after a medical assessment. The threshold generally used for medication is a BMI of 30 and above, or 27.5 and above where a weight-related condition such as type 2 diabetes, high blood pressure, fatty liver or obstructive sleep apnoea is present. Note that this is a higher goalpost than Malaysia's population definition of obesity, which the Ministry of Health Clinical Practice Guidelines on the Management of Obesity (2nd edition, 2023) set at a BMI above 27.5, with pre-obesity from 23. Being in the Malaysian obesity category does not by itself mean medication is the right step, and your doctor decides with you.

Your doctor reviews your medical and family history, current medications, and the reasons weight has been difficult to shift. Baseline tests usually include HbA1c and fasting glucose, a lipid profile, liver and kidney function, thyroid function, blood pressure and body composition where indicated. Screening is there to confirm that medication is appropriate, to identify conditions that need treating in parallel, and to give a baseline for follow-up. No prescription is issued without that assessment.

In the STEP 1 trial, adults on once-weekly semaglutide 2.4 mg lost an average of 14.9 percent of body weight at 68 weeks, compared with 2.4 percent on placebo, alongside lifestyle support (Wilding et al., New England Journal of Medicine, 2021). In SURMOUNT-1, adults on once-weekly tirzepatide lost an average of 15.0 to 20.9 percent at 72 weeks depending on dose, compared with 3.1 percent on placebo (Jastreboff et al., New England Journal of Medicine, 2022). These are group averages from trial populations, not a prediction for any individual, and they were achieved with structured diet and activity support.

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on two receptors, GIP and GLP-1, and is registered in Malaysia with the National Pharmaceutical Regulatory Agency. Average weight change in the tirzepatide trials was larger than in the semaglutide trials, but the studies were separate populations and the two medicines differ in side-effect profile, availability and cost. Your doctor weighs your history, tolerance and treatment goal rather than choosing by trial headline.

The common effects are digestive: nausea, reduced appetite, burping, constipation or loose stools, most often in the first weeks and after a dose increase. They usually settle as the body adapts, and slower dose escalation helps. Less common but important risks include gallbladder problems, pancreatitis and dehydration from persistent vomiting. You are told which symptoms warrant contacting the clinic straight away, and follow-up is scheduled rather than left to you to arrange.

It is not suitable in pregnancy or while breastfeeding, or for anyone planning pregnancy in the near term. It is avoided where there is a history of pancreatitis, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or a known allergy to the medicine. Caution applies with severe gastrointestinal disease, gallbladder disease, advanced kidney disease, diabetic retinopathy, and with insulin or sulfonylurea use, where doses may need adjusting. This is one reason the medicine is prescription-only.

Any substantial weight loss includes some lean tissue. The aim of treatment is to keep that share small, because muscle carries your strength, metabolic rate and long-term function. In practice that means adequate protein spread across the day, resistance training two to three times a week, and body composition tracking rather than the scale alone. If muscle loss looks disproportionate, the plan is adjusted.

Treatment starts at a low dose and increases in steps over several weeks, at the lowest effective dose for you rather than the maximum on the label. Appetite usually changes early, while weight change accumulates over months. Response is reviewed at set intervals, and if there is no meaningful response after an adequate trial at an adequate dose, continuing is not automatic - your doctor discusses alternatives.

Weight regain after stopping is common. In the STEP 1 extension, participants regained around two thirds of their weight loss in the year after treatment and lifestyle support were withdrawn (Wilding et al., Diabetes, Obesity and Metabolism, 2022). That is why maintenance is planned from the start: nutrition, training, sleep and follow-up are part of the treatment rather than an afterthought, and some patients continue medication at a lower dose while others taper off with continued support.

No. Semaglutide and tirzepatide are prescription-only medicines in Malaysia, and the Ministry of Health and the National Pharmaceutical Regulatory Agency have repeatedly warned about unregistered, counterfeit and illegally sold weight-loss products. Products bought from unknown online sellers can contain the wrong dose, the wrong substance or nothing active at all, and come with no assessment, no monitoring and no recourse if something goes wrong. Treatment at Hisential follows a medical assessment, with regulated supply and scheduled review.